CWA Asset Management Group LLC Boosts Position in Medpace Holdings, Inc. $MEDP

CWA Asset Management Group LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 119.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,827 shares of the company’s stock after buying an additional 1,536 shares during the period. CWA Asset Management Group LLC’s holdings in Medpace were worth $1,588,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MEDP. AQR Capital Management LLC increased its position in shares of Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares in the last quarter. Wasatch Advisors LP lifted its holdings in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Baillie Gifford & Co. boosted its position in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares during the period. Invesco Ltd. boosted its position in Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Epoch Investment Partners Inc. increased its holdings in Medpace by 11.4% in the 2nd quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock valued at $139,740,000 after purchasing an additional 45,435 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.30% of the stock is currently owned by company insiders.

Medpace Price Performance

Shares of MEDP stock opened at $452.51 on Monday. The company’s fifty day moving average price is $509.09 and its two-hundred day moving average price is $538.69. The firm has a market capitalization of $12.84 billion, a P/E ratio of 29.58, a P/E/G ratio of 2.17 and a beta of 1.44. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same period last year, the firm earned $3.67 earnings per share. The company’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on MEDP shares. Mizuho set a $582.00 price objective on Medpace in a research report on Wednesday, February 11th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and lowered their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Truist Financial dropped their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.